Enthorin Therapeutics

Enthorin Therapeutics is a private, clinical-stage biotech based in Cambridge, USA, leveraging a circuit-based therapeutic approach for CNS disorders. The company's lead asset, ENT-3379 for Fragile X Syndrome, is being advanced through a significant partnership with Mirum Pharmaceuticals. Founded by seasoned drug developers and a leading clinical neuroscientist, Enthorin is positioned to address major gaps in the treatment of conditions like Fragile X, Autism Spectrum Disorders, and Parkinson's Disease.

Circuit-based therapeutic platform targeting specific neural network dysfunction, integrated with biomarker development using advanced neuroimaging and digital cognitive assessments.

Competition is intense in CNS disorders, with many companies targeting similar indications. Differentiation will depend on demonstrating superior efficacy on core cognitive deficits and a favorable safety profile. The biomarker-driven, circuit-based approach could provide a competitive edge in clinical development.